Page 5 of 8 – SEC Filing
Explanatory Note: This Amendment No. 10 relates to and amends the Statement of Beneficial Ownership on Schedule 13D/A (“Schedule 13D/A”) of Tang Capital Partners, LP, a Delaware limited partnership, Tang Capital Management, LLC, a Delaware limited liability company, and Kevin C. Tang, a United States citizen (each, a “Reporting Person” and collectively, the “Reporting Persons”), initially filed jointly by the Reporting Persons with the U.S. Securities and Exchange Commission on August 7, 2014, and amended on September 2, 2014, September 30, 2014, December 16, 2014, May 15, 2015, June 24, 2015, August 21, 2015, March 7, 2016, March 6, 2017 and March 1, 2018 (as amended, the “Statement”), with respect to the Common Stock, $0.0001 par value (the “Common Stock”), of La Jolla Pharmaceutical Company, a California corporation (the “Issuer”).
Items 3 and 5 of the Statement are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Statement is hereby amended to add the following:
On March 2, 2018, Tang Capital Partners, LP purchased 10,000 shares of the Issuer’s Common Stock through the open market at a weighted-average price of $30.4435 per share.
On March 15, 2018, Tang Capital Partners, LP purchased 508,474 shares of the Issuer’s Common Stock through an underwritten public offering at a price of $29.50 per share.
Tang Capital Partners, LP holds some of its shares in commingled margin accounts with various financial institutions, which may extend margin credit to Tang Capital Partners, LP as and when required, to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts. The margin accounts may from time to time have debit balances. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the shares of Common Stock reported herein.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Statement is hereby amended and restated in its entirety as follows:
(a) Amount beneficially owned and percentage of class:
| Tang Capital Partners, LP | 4,138,893 shares, representing 16.2% of the class | |
| Tang Capital Management, LLC | 4,138,893 shares, representing 16.2% of the class | |
| Kevin C. Tang | 4,186,893 shares, representing 16.3% of the class |
Follow La Jolla Pharmaceutical Co (NASDAQ:LJPC)
Follow La Jolla Pharmaceutical Co (NASDAQ:LJPC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
